Odanacatib

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameOdanacatib
Drug Alias Name奥当卡替奥达卡替MK-822MK-0822MK-0822A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBone resorption factor inhibitorsCathepsin K inhibitors
TargetsBone resorption factorCathepsin K
Therapy Area/IndicationsVitamin D DeficiencyRenal InsufficiencyHepatic Insufficiency +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Frosst Canada LtdMerck Sharp & Dohme CorpMerck & Co Inc +[6] 
Active IndicationsN/A
Inactive IndicationsVitamin D DeficiencyRenal InsufficiencyHepatic Insufficiency +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG